jsmsJournal of Siberian Medical SciencesJournal of Siberian Medical Sciences2542-1174Federal state budgetary educational institution of higher education "Novosibirsk state medical university" of Ministry of Health of the Russian Federation (FSBEI HE NSMU MOH Russia)10.31549/2542-1174-2021-4-80-96jsms-778Research ArticleОБЗОРЫREVIEWПрогнозирование биологического поведения опухолей (на примере колоректального рака): ретроспектива и взгляд в будущееPrediction of the biological behavior of tumors: colorectal cancer case study. Retrospective and future outlookКонстантиновА. С.KonstantinovА. S.

Константинов Алексей Сергеевич  — врач-патологоанатом; ассистент кафедры патологической анатомии 

197758, г. Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68А

Aleksey S. Konstantinov — Pathologist; Assistant, Department of Pathological Anatomy 

Pesochniy town, 68А, Leningradskaya Str., Saint Petersburg, 197758 

konstantinov2007@gmail.comШелеховаК. В.ShelekhovaK. V.

Шелехова Ксения Владимировна — д-р мед. наук, заведующий патолого-анатомическим отделением; профессор, заведующий кафедрой патологической анатомии; старший преподаватель кафедры патологической анатомии 

Санкт-Петербург

Kseniya V. Shelekhova — Dr. Sci. (Med.), Head, Department of Pathological Anatomy; Professor, Head, Department of Pathological Anatomy; Senior Lecturer, Department of Pathological Anatomy

Saint Petersburg

ГБУЗ «Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический)»; ЧОУ ВО «Санкт-Петербургский медико-социальный институт»РоссияSaint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological); Saint Petersburg Medico-Social InstituteRussian FederationГБУЗ «Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический)»; ЧОУ ВО «Санкт-Петербургский медико-социальный институт»; ФГБВОУ ВО «Военно-медицинская академия имени С.М. Кирова» Министерства обороны РФРоссияSaint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological); Saint Petersburg Medico-Social Institute; Military Medical Academy named after S.M. KirovRussian Federation202120012022048096Copyright © Константинов А.С., Шелехова К.В., 20222022Константинов А.С., Шелехова К.В.Konstantinov А.S., Shelekhova K.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://jsms.elpub.ru/jour/article/view/778

Попытки определить биологическое поведение опухолей были неотъемлемой частью исследований в онкологии в течение почти 100 лет. За этот период было проведено множество работ по оценке ценности отдельных факторов, включающих как клиническую информацию о пациенте, так и патоморфологические особенности строения опухоли. Были предложены и модифицированы различные системы, комбинирующие всевозможные сочетания характеристик новообразования и эпидемиологических параметров. Таким образом, подходы к прогнозированию биологического поведения опухолей можно условно разделить на два типа: первый — аналитический подход — основан на выявлении отдельных морфологических или клинических факторов, влияющих на течение опухолевого процесса, и второй — системный подход, заключающийся в объединении нескольких связанных и взаимодействующих между собой признаков в единую прогностическую модель. Существующие системы классификации опухолей далеки от совершенства. Тем не менее общее мнение патологов, хирургов и клинических онкологов состоит в том, что параметры, характеризующие прогноз, заслуживают того, чтобы быть частью стандартного патоморфологического отчета для большинства опухолей.

Attempts to determine the biological behavior of tumors have been an integral part of research in oncology for nearly 100 years. During this period, many works have been carried out to assess the value of individual factors, including both clinical information about the patient and the pathomorphological features of the tumor. Various systems have been pro-posed and modified, combining all possible combinations of neoplasm characteristics and epidemiological parameters. Thus, approaches to predicting the biological behavior of tumors can be conditionally divided into two types: the first, an analytical approach, is based on revealing individual morphological or clinical factors that affect the course of the tumor process, and the second, a systemic approach, which consists in combining several related and interacting constitute signs into a unified predictive model. Existing tumor classification systems are far from perfect. Nevertheless, the general consensus among pathologists, surgeons, and clinical oncologists is that prognosis parameters deserve to be a part of the standard pathology report for most tumors.

колоректальный ракпрогнозированиемодельпротивоопухолевый иммунитетмикроокружениеcolorectal cancerprognosismodelantitumor immunitymicroenvironmentReferencesFaguet G.B. A brief history of cancer: age-old milestones underlying our current knowledge database // Int. J. Cancer. 2015. Vol. 13. P. 2022–2036. doi: 10.1002/ijc.29134.Faguet G.B. (2015). A brief history of cancer: age-old milestones underlying our current knowledge database. Int. J. Cancer, 13, 2022–2036. doi: 10.1002/ijc.29134.Costas-Chavarri A., Nandakumar G., Temin S. et al. Treatment of patients with early-stage colorectal cancer: ASCO resource-stratified guideline // J. Glob. Oncol. 2019. Vol. 5. P. 1–19. doi: 10.1200/JGO.18.00214.Costas-Chavarri A., Nandakumar G., Temin S. et al. (2019). Treatment of patients with early-stage colorectal cancer: ASCO resource-stratified guideline. J. Glob. Oncol., 5, 1–19. doi: 10.1200/JGO.18.00214.Watanabe T., Muro K., Ajioka Y. et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer // Int. J. Clin. Oncol. 2018. Vol. 23 (1). P. 1–34. doi: 10.1007/s10147-017-1101-6.Watanabe T., Muro K., Ajioka Y. et al. (2018). Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int. J. Clin. Oncol., 23 (1), 1–34. doi: 10.1007/s10147-017-1101-6.Broders A.C. Squamous cell epithelioma of the lip: A study of five hundred and thirty-seven cases // JAMA. 1920. Vol. 74 (10). P. 656–664. doi: 10.1001/jama.1920.02620100016007.Broders A.C. (1920). Squamous cell epithelioma of the lip: A study of five hundred and thirty-seven cases. JAMA, 74 (10), 656–664. doi: 10.1001/jama.1920.02620100016007.Broders A.C. Milestones in a Medical Career [unpublished memoir]. 1960. 74 p. History of Medicine Library, Mayo Foundation, Rochester, MN (MHU No. 0670).Broders A.C. (1960). Milestones in a Medical Career [unpublished memoir]. 74 p. History of Medicine Library, Mayo Foundation, Rochester, MN (MHU No. 0670).Dukes C. Histological grading of rectal cancer // Proc. Royal Soc. Med. 1937. Vol. 30 (4). P. 371–376.Dukes C. (1937). Histological grading of rectal cancer. Proc. Royal Soc. Med., 30 (4), 371–376.Broders A.C., Buie L.A., Laird D.R. Prognosis in carcinoma of the rectum: a comparison of the Broders and Dukes methods of classification // JAMA. 1940. Vol. 115 (13). P. 1066–1071. doi: 10.1001/jama.1940.02810390006002.Broders A.C., Buie L.A., Laird D.R. (1940). Prognosis in carcinoma of the rectum: a comparison of the Broders and Dukes methods of classification. JAMA, 115 (13), 1066–1071. doi: 10.1001/jama.1940.02810390006002.Clinical Practice Guidelines in Oncology. Colon cancer. Version 2.2021 // NCCS guidelines. 2021. P. 1–198.Clinical Practice Guidelines in Oncology. Colon cancer. Version 2.2021 (2021). NCCS guidelines, 1–198.Argilés G., Tabernero J., Labianca R. et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2020. Vol. 31 (10). P. 1291–1305. doi: 10.1016/j.annonc.2020.06.022.Argilés G., Tabernero J., Labianca R. et al. (2020). Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 31 (10), 1291–1305. doi: 10.1016/j.annonc.2020.06.022.Pagès F., Mlecnik B., Marliot F. et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study // Lancet. 2018. Vol. 391 (10135). P. 2128–2139. doi: 10.1016/S0140-6736(18)30789-X.Pagès F., Mlecnik B., Marliot F. et al. (2018). International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, 391 (10135), 2128–2139. doi: 10.1016/S0140-6736(18)30789-X.Konishi T., Shimada Y., Lee L.H. et al. Poorly differentiated clusters predict colon cancer recurrence: an indepth comparative analysis of invasive-front prognostic markers // Am. J. Surg. Pathol. 2018. Vol. 42 (6). P. 705–714. doi: 10.1097/PAS.0000000000001059.Konishi T., Shimada Y., Lee L.H. et al. (2018). Poorly differentiated clusters predict colon cancer recurrence: an in-depth comparative analysis of invasive-front prognostic markers. Am. J. Surg. Pathol., 42 (6), 705– 714. doi: 10.1097/PAS.0000000000001059.WHO Classification of Tumours. 5th ed. Digestive system tumours / ed. by the WHO Classification of Tumours Editorial Board. IARC. 2019. 635 p.WHO Classification of Tumours. 5th ed. Digestive System Tumours / ed. by the WHO Classification of Tumours Editorial Board. (2019). IARC, 635 p.Betge J., Pollheimer M.J., Lindtner R.A. et al. Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting // Cancer. 2012. Vol. 118 (3). P. 628–638. doi: 10.1002/cncr.26310.Betge J., Pollheimer M.J., Lindtner R.A. et al. (2012). Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer, 118 (3), 628–638. doi: 10.1002/cncr.26310.Messenger D.E., Driman D.K., Kirsch R. Developments in the assessment of venous invasion in colorectal cancer: implications for future practice and patient outcome // Hum. Pathol. 2012. Vol. 43 (7). P. 965–973. doi: 10.1016/j.humpath.2011.11.015.Messenger D.E., Driman D.K., Kirsch R. (2012). Developments in the assessment of venous invasion in colorectal cancer: implications for future practice and patient outcome. Hum. Pathol., 43 (7), 965–973. doi: 10.1016/j.humpath.2011.11.015.Ouchi K., Sugawara T., Ono H. et al. Histologic features and clinical significance of venous invasion in colorectal carcinoma with hepatic metastasis // Cancer. 1996. Vol. 78 (11). P. 2313–2317. doi: 10.1002/(sici)1097-0142(19961201)78:11<2313::aid-cncr7>3.0.co;2-n.Ouchi K., Sugawara T., Ono H. et al. (1996). Histologic features and clinical significance of venous invasion in colorectal carcinoma with hepatic metastasis. Cancer, 78 (11), 2313–2317. doi: 10.1002/(sici)1097-0142(19961201)78:11<2313::aid-cncr7>3.0.co;2-n.Gomez D., Zaitoun A.M., De Rosa A. et al. Critical review of the prognostic significance of pathological variables in patients undergoing resection for colorectal liver metastases // HPB (Oxford). 2014. Vol. 16 (9). P. 836–844. doi: 10.1111/hpb.12216.Gomez D., Zaitoun A.M., De Rosa A. et al. (2014). Critical review of the prognostic significance of pathological variables in patients undergoing resection for colorectal liver metastases. HPB (Oxford), 16 (9), 836–844. doi: 10.1111/hpb.12216.Hu G., Li L., Hu K. Clinical implications of perineural invasion in patients with colorectal cancer // Medicine (Baltimore). 2020. Vol. 99 (17): e19860. doi: 10.1097/MD.0000000000019860.Hu G., Li L., Hu K. (2020). Clinical implications of perineural invasion in patients with colorectal cancer. Medicine (Baltimore), 99 (17), e19860. doi: 10.1097/MD.0000000000019860.Ueno H., Shirouzu K., Eishi Y. et al; Study Group for Perineural Invasion projected by the Japanese Society for Cancer of the Colon and Rectum (JSCCR). Characterization of perineural invasion as a component of colorectal cancer staging // Am. J. Surg. Pathol. 2013. Vol. 37 (10). P. 1542–1549. doi: 10.1097/PAS.0b013e318297ef6e.Ueno H., Shirouzu K., Eishi Y. et al. (2013). Study Group for Perineural Invasion projected by the Japanese Society for Cancer of the Colon and Rectum (JSCCR). Characterization of perineural invasion as a component of colorectal cancer staging. Am. J. Surg. Pathol., 37 (10), 1542–1549. doi: 10.1097/PAS.0b013e318297ef6e.Ozturk M.A., Dane F., Karagoz S. et al. Is perineural invasion (PN) a determinant of disease-free survival in early-stage colorectal cancer? // Hepatogastroenterology. 2015. Vol. 62 (137). P. 59–64.Ozturk M.A., Dane F., Karagoz S. et al. (2015). Is perineural invasion (PN) a determinant of disease-free survival in early-stage colorectal cancer? Hepatogastroenterology, 62 (137), 59–64.Petrelli F., Pezzica E., Cabiddu M. et al. Tumour budding and survival in stage ii colorectal cancer: a systematic review and pooled analysis // J. Gastrointest. Cancer. 2015. Vol. 46 (3). P. 212–218. doi: 10.1007/s12029-015-9716-1.Petrelli F., Pezzica E., Cabiddu M. et al. (2015). Tumour budding and survival in stage ii colorectal cancer: a systematic review and pooled analysis. J. Gastrointest. Cancer, 46 (3), 212–218. doi: 10.1007/s12029-015-9716-1.Lugli A., Kirsch R., Ajioka Y. et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016 // Mod. Pathol. 2017. Vol. 30 (9). P. 1299–1311. doi: 10.1038/modpathol.2017.46.Lugli A., Kirsch R., Ajioka Y. et al. (2017). Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod. Pathol., 30 (9), 1299–1311. doi: 10.1038/modpathol.2017.46.van Wyk H.C., Roseweir A., Alexander P. et al. The relationship between tumor budding, tumor microenvironment, and survival in patients with primary operable colorectal cancer // Ann. Surg. Oncol. 2019. Vol. 26 (13). P. 4397–4404. doi: 10.1245/s10434-019-07931-6.van Wyk H.C., Roseweir A., Alexander P. et al. (2019). The relationship between tumor budding, tumor microenvironment, and survival in patients with primary operable colorectal cancer. Ann. Surg. Oncol., 26 (13), 4397–4404. doi: 10.1245/s10434-019-07931-6.UICC Manual of Clinical Oncology. 9th ed. / ed. by B. O’Sullivan, J.D. Brierley, A.K. D’Cruz et al. Wiley Blackwell. 2015. 856 p.O’Sullivan B., Brierley J.D., D’Cruz A.K. et al. (eds.) UICC Manual of Clinical Oncology. 9th ed. (2015). Wiley Blackwell. 856 p.Mehta A., Goswami M., Sinha R., Dogra A. Histopathological significance and prognostic impact of tumor budding in colorectal cancer // Asian. Pac. J. Cancer. Prev. 2018. Vol. 19 (9). P. 2447–2453. doi: 10.22034/APJCP.2018.19.9.2447.Mehta A., Goswami M., Sinha R., Dogra A. (2018). Histopathological significance and prognostic impact of tumor budding in colorectal cancer. Asian. Pac. J. Cancer. Prev., 19 (9), 2447–2453. doi: 10.22034/APJCP.2018.19.9.2447.Mittal V. Epithelial mesenchymal transition in tumor metastasis // Annu. Rev. Pathol. 2018. Vol. 13. P. 395– 412. doi: 10.1146/annurev-pathol-020117-043854.Mittal V. (2018). Epithelial mesenchymal transition in tumor metastasis. Annu. Rev. Pathol., 13, 395–412. doi: 10.1146/annurev-pathol-020117-043854.Yamada N., Sugai T., Eizuka M. et al. Tumor budding at the invasive front of colorectal cancer may not be associated with the epithelial-mesenchymal transition // Hum. Pathol. 2017. Vol. 60 (9). P. 151–159. doi: 10.1016/j.humpath.2016.10.007.Yamada N., Sugai T., Eizuka M. et al. (2017). Tumor budding at the invasive front of colorectal cancer may not be associated with the epithelial-mesenchymal transition. Hum. Pathol., 60 (9), 151–159. doi: 10.1016/j.humpath.2016.10.007.Virchow R. Cellular pathology. As based upon physiological and pathological histology. Lecture XVI — Atheromatous affection of arteries. 1858 // Nutr. Rev. 1989. Vol. 47 (1). P. 23–25. doi: 10.1111/j.1753-4887.1989.tb02747.x.Virchow R. (1989). Cellular pathology. As based upon physiological and pathological histology. Lecture XVI — Atheromatous affection of arteries. 1858. Nutr. Rev., 47 (1), 23–25. doi: 10.1111/j.1753-4887.1989.tb02747.x.Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation // Cell. 2011. Vol. 144 (5). P. 646–674. doi: 10.1016/j.cell.2011.02.013.Hanahan D., Weinberg R.A. (2011). Hallmarks of cancer: the next generation. Cell, 144 (5), 646–674. doi: 10.1016/j.cell.2011.02.013.Hui L., Chen Y. Tumor microenvironment: Sanctuary of the devil // Cancer Lett. 2015. Vol. 368 (1). P. 7–13. doi: 10.1016/j.canlet.2015.07.039.Hui L., Chen Y. (2015). Tumor microenvironment: Sanctuary of the devil. Cancer Lett., 368 (1), 7–13. doi: 10.1016/j.canlet.2015.07.039.Hellström I., Hellström K.E., Pierce G.E., Yang J.P. Cellular and humoral immunity to different types of human neoplasms // Nature. 1968. Vol. 220 (5174). P. 1352–1354. doi: 10.1038/2201352a0.Hellström I., Hellström K.E., Pierce G.E., Yang J.P. (1968). Cellular and humoral immunity to different types of human neoplasms. Nature, 220 (5174), 1352– 1354. doi: 10.1038/2201352a0.Dirnhofer S., Zippelius A. Cancer immunology, inflammation, and tolerance: an introduction // Virchows Arch. 2019. Vol. 474 (4). P. 405–406. doi: 10.1007/s00428-019-02547-3.Dirnhofer S., Zippelius A. (2019). Cancer immunology, inflammation, and tolerance: an introduction. Virchows Arch., 474 (4), 405–406. doi: 10.1007/s00428-019-02547-3.Rhee I. Diverse macrophages polarization in tumor microenvironment // Arch. Pharm. Res. 2016. Vol. 39 (11). P. 1588–1596. doi: 10.1007/s12272-016-0820-y.Rhee I. (2016). Diverse macrophages polarization in tumor microenvironment. Arch. Pharm. Res., 39 (11), 1588–1596. doi: 10.1007/s12272-016-0820-y.Chen Y., Song Y., Du W. et al. Tumor-associated macrophages: an accomplice in solid tumor progression // J. Biomed. Sci. 2019. Vol. 26 (1). P. 78. doi: 10.1186/s12929-019-0568-z.Chen Y., Song Y., Du W. et al. (2019). Tumor-associated macrophages: an accomplice in solid tumor progression. J. Biomed. Sci., 26 (1), 78. doi: 10.1186/s12929-019-0568-z.Hagemann T., Lawrence T., McNeish I. et al. “Re-educating” tumor-associated macrophages by targeting NF-κB // J. Exp. Med. 2008. Vol. 205 (6). P. 1261–1268. doi: 10.1084/jem.20080108.Hagemann T., Lawrence T., McNeish I. et al. (2008). “Re-educating” tumor-associated macrophages by targeting NF-κB. J. Exp. Med., 205 (6), 1261–1268. doi: 10.1084/jem.20080108.Shime H., Matsumoto M., Oshiumi H. et al. Tolllike receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors // Proc. Natl. Acad. Sci. USA. 2012. Vol. 109 (6). P. 2066–2071. doi: 10.1073/pnas.1113099109.Shime H., Matsumoto M., Oshiumi H. et al. (2012). Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc. Natl. Acad. Sci. USA, 109 (6), 2066–2071. doi: 10.1073/pnas.1113099109.Pyonteck S.M., Akkari L., Schuhmacher A.J. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression // Nat. Med. 2013. Vol. 19 (10). P. 1264–1272. doi: 10.1038/nm.3337.Pyonteck S.M., Akkari L., Schuhmacher A.J. et al. (2013). CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med., 19 (10), 1264–1272. doi: 10.1038/nm.3337.Algars A., Irjala H., Vaittinen S. et al. Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients // Int. J. Cancer. 2012. Vol. 131 (4). P. 864–873. doi: 10.1002/ijc.26457.Algars A., Irjala H., Vaittinen S. et al. (2012). Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int. J. Cancer, 131 (4), 864–873. doi: 10.1002/ijc.26457.Tuccitto A., Shahaj E., Vergani E. et al. Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy // Virchows Arch. 2019. Vol. 474 (4). P. 407–420. doi: 10.1007/s00428-018-2477-z.Tuccitto A., Shahaj E., Vergani E. et al. (2019). Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy. Virchows Arch., 474 (4), 407–420. doi: 10.1007/s00428-018-2477-z.Komi D.E.A., Redegeld F.A. Role of mast cells in shaping the tumor microenvironment // Clin. Rev. Allergy Immunol. 2020. Vol. 58 (3). P. 313–325. doi: 10.1007/s12016-019-08753-w.Komi D.E.A., Redegeld F.A. (2020). Role of mast cells in shaping the tumor microenvironment. Clin. Rev. Allergy Immunol., 58 (3), 313–325. doi: 10.1007/s12016-019-08753-w.Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis // Nat. Med. 2013. Vol. 19 (11). P. 1423–1437. doi: 10.1038/nm.3394.Quail D.F., Joyce J.A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nat. Med., 19 (11), 1423–1437. doi: 10.1038/nm.3394.The Basics of Cancer Immunotherapy / ed. by H. Dong, S.N. Markovic. Springer, 2018. 172 p.Dong H., Markovic S.N. (eds.) (2018). The Basics of Cancer Immunotherapy. Springer, 172 p.Ohue Y., Nishikawa H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? // Cancer Sci. 2019. Vol. 110 (7). P. 2080–2089. doi: 10.1111/cas.14069.Ohue Y., Nishikawa H. (2019). Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? Cancer Sci., 110 (7), 2080–2089. doi: 10.1111/cas.14069.Galon J., Lanzi A. Immunoscore and its introduction in clinical practice // Q. J. Nucl. Med. Mol. Imaging. 2020. Vol. 64 (2). P. 152–161. doi: 10.23736/S1824-4785.20.03249-5.Galon J., Lanzi A. (2020). Immunoscore and its introduction in clinical practice. Q. J. Nucl. Med. Mol. Imaging, 64 (2), 152–161. doi: 10.23736/S1824-4785.20.03249-5.Zamarron B.F., Chen W. Dual roles of immune cells and their factors in cancer development and progression // Int. J. Biol. Sci. 2011. Vol. 7 (5). P. 651–658. doi: 10.7150/ijbs.7.651.Zamarron B.F., Chen W. (2011). Dual roles of immune cells and their factors in cancer development and progression. Int. J. Biol. Sci., 7 (5), 651–658. doi: 10.7150/ijbs.7.651.Steyerberg E.W., Moons K.G.M., van der Windt D.A. et al. Prognosis Research Strategy (PROGRESS) 3: prognostic model research // PLoS Med. 2013. Vol. 10 (2): e1001381. doi: 10.1371/journal.pmed.1001381.Steyerberg E.W., Moons K.G.M., van der Windt D.A. et al. (2013). Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med., 10 (2), e1001381. doi: 10.1371/journal.pmed.1001381.Алтыбаев C.H. Клинико-морфологические особенности аденокарциномы прямой кишки, связанные с лимфогенным метастазированием: автореф. дис. … канд. мед. наук. Томск, 2018. 25 с.Altybaev S.N. (2018). Clinical and morphological features of rectal adenocarcinoma associated with lymphogenous metastasis. Cand. Sci. (Med.) thesis, abstract. Tomsk, 25 p. (In Russ.)Рачковский К.В. Особенности экспрессии регуляторов аутофагии m-TOR и Beclin-1 в опухоли при колоректальном раке: автореф. дис. … канд. мед. наук. Томск, 2019. 26 с.Rachkovskiy K.V. (2019). Features of expression of autophagy regulators m-TOR and Beclin-1 in tumors in colorectal cancer. Cand. Sci. (Med.) thesis, abstract. Tomsk, 26 p. (In Russ.)Giraldo N.A., Peske J.D., Sautès-Fridman C., Fridman W.H. Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology // Virchows Arch. 2019 Vol. 474 (4). P. 463–474. doi: 10.1007/s00428-018-02517-1.Giraldo N.A., Peske J.D., Sautès-Fridman C., Fridman W.H. (2019). Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Arch., 474 (4), 463–474. doi: 10.1007/s00428-018-02517-1.

The authors declare that there are no conflicts of interest present.